drugset
Drugs / Velneperit
last change Feb 2011 re-read 9 days ago

Velneperit

also known as S-2367

Small molecule targets NPY5R via inhibition

Developed for
obesity disorder
Investigated by
Shionogi

Trials 4

today NCT01126970 · Ph 2 NCT00788528 · Ph 2 NCT00748605 · Ph 2 NCT00747929 · Ph 2
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT01126970 Apr 2010 → Jan 2011 obesity disorder Shionogi Completed No outcome recorded
Phase 2 NCT00788528 Aug 2008 → Feb 2010 obesity disorder Shionogi Completed No outcome recorded
Phase 2 NCT00748605 Jun 2007 → Nov 2008 obesity disorder Shionogi Completed No outcome recorded
Phase 2 NCT00747929 Jun 2007 → Nov 2008 obesity disorder Shionogi Completed No outcome recorded

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 5 sources stand behind the page.

FieldValueCited text
Known as velneperit “S-2367 (velneperit)” NCT00788528 ↗
1

NCT01126970 ↗
Known as S-2367 ClinicalTrials.gov intervention name — accepted as the source's own label NCT00788528 ↗
2

NCT00748605 ↗

NCT00747929 ↗
Action Inhibit “Neuropeptide Y receptor type 5 antagonist” CHEMBL2016681 ↗
Modality Small molecule — CHEMBL2016681 ↗
Route Oral “administered orally once-a-day” NCT00747929 ↗
Target NPY5R “Neuropeptide Y receptor type 5 antagonist” CHEMBL2016681 ↗